Want to know if you had COVID-19?

T cells have the answer.*

Want to know if you had COVID-19?

T cells have the answer.*

Opt In Email

Be the first to know about T-Detect news, offers and updates.

Sign Up

How it works

Order Patient

1. Order

Answer some eligibility questions and submit payment.
Order now.

Account Set Up

2. Test authorization

An independent healthcare provider will review your responses and, if appropriate, authorize your test.

Blood Draw

3. Blood draw

A certified phlebotomist will draw your blood.

Results

4. Results

Adaptive Biotechnologies will process the blood sample and share results with you via a secure email from PWNHealth.

Estimated time for test results is 7-10 days from shipment of the blood sample (including 5-7 days for lab processing**).

Adaptive has partnered with PWNHealth, an independent healthcare provider network, to authorize tests, when appropriate.

**Lab processing begins once all required provider and patient information is validated.

Why T cells?

  • T cells are the first responders of the adaptive immune system.
  • T-cell responses can persist in the blood long after antibody responses wane.1, 2
  • Each T cell identifies a very specific piece of the virus and collectively, your overall T-cell response can recognize many different parts of the virus. Most antibody tests only look for one part of the virus (spike protein).3
  • In a study, T-cell responses were detected up to 10 months after initial COVID-19 infection with 90% sensitivity.4

Time since infection

T cells persist longer than antibodies

* Based on prior research on other coronavirus T-cell response. 2, 5

Patients Specificity Data

Specificity of a test is its ability to designate an individual who does not have a disease as negative. A highly specific test means that there are few false positive results.8

T cells vs. antibodies

In some studies, T-cell testing outperformed leading antibody tests.6,7

Sensitivity

Patients Data Sensitivity

Sensitivity based on positive percent agreement (PPA) with PCR testing.
Sensitivity refers to a test’s ability to designate an individual with disease as positive. A highly sensitive test means that there are few false negative results, and thus fewer cases of disease are missed.8

References

  1. Tay MZ, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020.
  2. Ng O, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016.
  3. Zuo J, et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021.
  4. Data on file. Adaptive Biotechnologies. 2021.
  5. Channappanavar R, et al. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014.
  6. Dalai, S, et al. Clinical Validation of a Novel T-cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection. medRxiv. 2021.
  7. Elyanow R., et al. T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity. medRxiv. 2021.
  8. “Disease Screening – Statistics Teaching Tools.” New York State Department of Health website. Updated April 1999. Accessed December 9, 2021.

*The performance of this test has not been established in individuals that have received a COVID-19 vaccine.

T-Detect™ COVID is not FDA cleared or approved. It is authorized for emergency use under an Emergency Use Authorization (EUA). 

Testing of venous whole blood using K2 EDTA specimens is limited to laboratories designated by Adaptive Biotechnologies Corporation that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meets the requirements to perform high complexity tests as described in the T-Detect COVID Test Standard Operating Procedure that was reviewed by the FDA under this EUA.

This test has been authorized only for detecting and identifying the presence of an adaptive T-cell immune response to SARS-CoV-2, not for any other viruses or pathogens.

The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.  

The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

T-Detect™ COVID is not indicated for use in patients under age 18.